[Paper-level Aggregated] PMCID: PMC8887939

Evidence Type(s): Predictive

Summary: Mutation: A775dupYVMA | Summary: The HER2 A775dupYVMA mutation is associated with an overall response rate (ORR) of 20.0%, indicating its potential predictive value for therapy response.

Evidence Type: Predictive Mutation: G776delinsVC | Summary: The G776delinsVC mutation shows an ORR of 27.3%, suggesting it may also have predictive implications for treatment response.

Gene→Variant (gene-first): ERBB2(2064):A775dupYVMA ERBB2(2064):G776delinsVC

Genes: ERBB2(2064)

Variants: A775dupYVMA G776delinsVC

[Paragraph-level] PMCID: PMC8887939 Section: RESULTS PassageIndex: 11

Evidence Type(s): Predictive

Summary: Evidence Type: Predictive | Mutation: A775dupYVMA | Summary: The HER2 A775dupYVMA mutation is associated with an overall response rate (ORR) of 20.0%, indicating its potential predictive value for therapy response. Evidence Type: Predictive | Mutation: G776delinsVC | Summary: The G776delinsVC mutation shows an ORR of 27.3%, suggesting it may also have predictive implications for treatment response.

Gene→Variant (gene-first): 2064:A775dupYVMA 2064:G776delinsVC

Genes: 2064

Variants: A775dupYVMA G776delinsVC

[Paper-level Aggregated] PMCID: PMC8887939

Evidence Type(s): Prognostic, Oncogenic

Justification: Prognostic: The text provides data on overall response rates (ORR), median duration of response (DoR), and median progression-free survival (PFS) associated with specific mutations, indicating their potential to predict clinical outcomes. Oncogenic: The mention of specific mutations (A775dupYVMA and G776delinsVC) in the context of their frequency and associated clinical outcomes suggests a role in tumorigenesis.

Gene→Variant (gene-first): ERBB2(2064):A775dupYVMA ERBB2(2064):G776delinsVC

Genes: ERBB2(2064)

Variants: A775dupYVMA G776delinsVC

[Paragraph-level] PMCID: PMC8887939 Section: RESULTS PassageIndex: 11

Evidence Type(s): Predictive, Diagnostic

Justification: Predictive: The passage discusses the overall response rate (ORR) and median progression-free survival (PFS) associated with the HER2 insertion mutations, indicating a correlation with treatment response. Diagnostic: The mention of the frequency of the HER2 Y772_A775dupYVMA mutation in patients suggests its role in defining or classifying a specific disease subtype.

Gene→Variant (gene-first): 2064:A775dupYVMA 2064:G776delinsVC

Genes: 2064

Variants: A775dupYVMA G776delinsVC

[Paragraph-level] PMCID: PMC8887939 Section: RESULTS PassageIndex: 11

Evidence Type(s): Predictive, Diagnostic

Justification: Predictive: The passage discusses the overall response rate (ORR) and median progression-free survival (PFS) associated with the HER2 insertion mutations, indicating a correlation with treatment response. Diagnostic: The mention of the frequency of the HER2 Y772_A775dupYVMA mutation in patients suggests its role in defining or classifying a specific disease subtype.

Gene→Variant (gene-first): 2064:A775dupYVMA 2064:G776delinsVC

Genes: 2064

Variants: A775dupYVMA G776delinsVC